Table 1 Patient characteristics in total and matched cohorts
Characteristic | Total set | Matched set | ||||
|---|---|---|---|---|---|---|
n-TPE (n = 109) | TPE (n = 218) | p | n-TPE (n = 78) | TPE (n = 116) | p | |
Age, yr | 38 {32.5, 45} | 37 {31, 45} | 0.462 | 38 {32, 45} | 37 {31, 45} | 0.715 |
Sex, male% | 74 (67.89%) | 164 (75.23%) | 0.188 | 53 (67.95%) | 86 (74.14%) | 0.417 |
BMI | 25.10 {22.99, 27.78} | 24.22 {22.57, 26.60} | 0.059 | 24.69 {22.90, 27.73} | 24.66 {23.00, 27.01} | 0.939 |
TG | 16.76 {13.75, 20.07} | 18.17 {16.08, 21.55} | 0.002a | 17.29 {13.64, 21.24} | 17.81 {15.77, 20.30} | 0.184 |
Atlanta | ||||||
SAP, n% | 36 (33.28%) | 91 (41.73%) | 0.149 | 31 (39.74%) | 44 (37.93) | 0.881 |
MSAP, n% | 22 (20.18%) | 36 (16.51%) | 0.000 | 17 (21.79%) | 22 (18.97%) | 0.715 |
MAP, n% | 51 (46.79%) | 91 (41.74%) | 0.409 | 30 (38.46%) | 50 (43.10%) | 0.554 |
Coexisting disease (n %) | ||||||
DM | 80 (73.39%) | 177 (81.19%) | 0.117 | 59 (75.64%) | 94 (81.03%) | 0.376 |
Alcoholic | 23 (21.10%) | 56 (25.69%) | 0.412 | 19 (24.36%) | 30 (25.86%) | 0.867 |
Concomitant treatment | ||||||
Fenofibrate (started within 5 days of onset) | 55.46% (60/109) | 49.08% (107/218) | 0.348 | 57.69% (45/78) | 49.14% (57/116) | 0.240 |
Fenofibrate (started after 5 days of onset) | 8.26% (29/109) | 27.06% (59/218) | 1.000 | 32.05% (25/78) | 25.86% (30/116) | 0.417 |
Standardized differenceb | ||||||
Pre-matched (95% CI) | Matched (95% CI) | |||||
TG | 0.009 (-0.221–0.239) | 0.106 (-0.181–0.394) | ||||
BMI | 0.183 (-0.047–0.414) | 0.012 (-0.275–0.299) | ||||
Age | 0.075 (-0.155–0.305) | 0.073 (-0.214–0.360) | ||||
Sex | 0.163 (-0.068–0.393) | 0.137 (-0.151–0.424) | ||||
Severity | 0.184 (-0.047–0.414) | 0.1 (-0.187–0.388) | ||||